Skip to NavigationSkip to content

Type 1 diabetes

Fast-acting mealtime insulin approved for children with diabetes in Canada

Photo by Alan Levine

Health Canada has approved Novo Nordik’s Fiasp, a faster acting mealtime insulin, for children aged 2 and above with type 1 or type 2 diabetes.

The regulatory body also approved Fiasp to include use in insulin infusion pumps for the improvement of glycemic control.

Dave Prowten, President and CEO of JDRF Canada, said on the approval: “We welcome the paediatric approval of Fiasp for younger Canadians, providing greater choice for effective disease management to support easier, healthier and safer lives for young people with type 1 diabetes.”

Insulin pumps tied to over 2,000 injuries recalled

Over 300,000 insulin pumps have been recalled by Medtronic after injuries and one death were reported due to devices malfunctioning.

The company received 26,421 complaints regarding the malfunctions, which caused 2,175 injuries. The FDA said this is a Class I recall which is the most serious type of recall.

Type 2 diabetes cases up 40% in Scotland

According to a new study, Scotland’s cases of type 2 diabetes has increased by 40% over the last 10 years.

Diabetes Scotland's figures show cases rose from 190,772 to 267,615 between 2008 and 2018. They also estimate that 26,347 people are living with the condition.

Diabetes Scotland said the figures prove this is now an urgent public health crisis. Angela Mitchel, the Director of the organization, said: “Solving the crisis depends on decisive action led by both the UK and Scottish governments, supported by industry and delivered across our society.

Novo Nordisk to offer US patient’s in immediate need free insulin

Novo Nordisk said it would offer free, one-time supply of insulin to those in need, amidst rising insulin prices.

Novo has said that patients with a prescription can get the free insulin, in a supply of up to three vials or two packs of pens of its insulin. But after this they have to find a longer-term solution.

This follows a move back in September where they allowed their US patients to buy three vials, or two packs of pens, of its analogue insulins for $99.

FDA approves artificial pancreas developed by the University of Virginia

The FDA has approved an artificial pancreas system based on technology from the University of Virginia's Center for Diabetes Technology.

The University says that the artificial pancreas system, called Control-IQ and manufactured by Tandem Diabetes Care, tracks blood glucose levels with a continuous glucose monitor (Dexcom G6 CGM) and automatically delivers the hormone insulin as needed.

Using this, means that pateints do not have to test their blood sugar levels multiple times a day by fingerstick, or deliver insulin by multiple daily injections.

Promising Phase 3 data for Sanofi's Toujeo secures CHMP recommendation of label expansion in type 1 diabetes

Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to reveal positive new Phase 3 data on Toujeo (insulin glargine 300 Units/mL) in paediatric and adolescent type 1 diabetes patients between six and 17 years old.

Sanofi and Lexicon's Zynquista scores EU approval for type 1 diabetes patients

The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific patients with type 1 diabetes (T1D), it has been revealed.

The oral SGLT1 and 2 inhibitor was approved in both 200 mg and 400 mg doses as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus and a body mass index ≥ 27 kg/m2, who could not achieve adequate control despite optimal insulin therapy.

Insider Interview: The diabetes/mental health connection

Published on 03/12/18 at 03:55pm

Michael Connellan, Head of External Affairs at the type 1 diabetes charity JDRF, discusses the results of a recent survey which suggests that more than three quarters of people with diabetes suffer from stress, anxiety attacks or bouts of deep depression. Meanwhile, 30% of respondents recorded battling an eating condition, while 19% admitted self-harming. Nearly half (46%) claimed their problems started after their diagnosis.

Novo Nordisk's Fiasp shows strong blood sugar control in under-18 type 1 diabetes patients

New data unveiled by Novo Nordisk has shown that its insulin injection Fiasp (fast-acting insulin aspart) could provide a better option for child and adolescent patients with type 1 diabetes to manage their blood sugar levels compared to existing therapies when administered multiple times a day.

The data, presented at the 44th Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), demonstrated that patients using Fiasp at mealtimes saw “superior reductions in overall blood sugar levels (HbA1c)”, compared to conventional insulin aspart.

Pioneering immunotherapy halts progression of type 1 diabetes

In a first for the disease area, an immunotherapy treatment for diabetes, developed by researchers at King’s College London and Cardiff University, has proven its ability to halt the progression of the type 1 form of the illness.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches